Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628651 · ClinicalTrials.gov registry record
Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
A clinical trial, sponsored by Exact Sciences Corporation.
- Completed
- Registry status
- 2,150
- Enrollment target
NCT03628651 is a clinical trial that has completed, run by Exact Sciences Corporation. The registered enrollment target is 2,150 participants.
The verdict
NCT03628651 has completed, sponsored by Exact Sciences Corporation.
- COMPLETED
- Registry status
- 2,150 participants
- Enrollment target
Study Summary
The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,150 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2020-03-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03628651
The ClinicalTrials.gov registry entry for NCT03628651 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exact Sciences Corporation, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT03628651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03628651 about?
NCT03628651 is a clinical study titled "Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma". The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).
What is the current status of trial NCT03628651?
This trial is currently completed. The enrollment target is 2,150 participants. The study started on 2018-04-02. Estimated completion is 2020-03-11.
What interventions are being tested in trial NCT03628651?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03628651?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.